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Introduction
Many severe diseases resulting from infections, such as 
meningitis, dengue, or leprosy, are relatively rare within 
the  human  population  when  compared  with  the  often 
ubiquitous  nature  of  the  causative  infectious  agent  in 
specific world regions. While antibody responses to these 
organisms can be measured in large percentages of these 
populations, disease leading to hospitalization affects a 
small minority. This has led to the realization that the 
type of host response made to an infectious encounter 
may  play  a  large  role  in  determining  the  outcome. 
Understanding  how  most  people  successfully  contain 
these infectious challenges may lead to the development 
of  novel  therapeutics  for  those  individuals  at  risk  of 
severe disease.
This application of human genetics has proven insight­
ful in those rare humans who are broadly susceptible to 
infections, where Mendelian genetic linkage approaches 
have  revealed  highly  penetrant  mutations  that  cause 
disease.  With  the  advent  of  genome­wide  association 
study (GWAS) technology, the field has been looking to 
see  if  the  lessons  learnt  can  be  carried  over  to  more 
common infectious diseases.
Severe combined immune deficiency and partial 
immune deficiency
The first studies of immune response defects and infec­
tious disease outcomes strongly suggested that infectious 
diseases would have shared pathways to disease. Severe 
combined immune deficiency (SCID) ­ a genetic disorder 
that affects the adaptive immune system ­ demonstrates 
the  importance  of  the  immune  system  in  protection 
against infection, as patients with SCID quickly succumb 
to  life­threatening  sepsis  from  a  very  wide  range  of 
infectious agents. The gene responsible for the majority 
of  SCID  cases,  CD132  (the  common  γ­chain),  was 
identified  using  the  traditional  linkage  approach  [1­3]. 
Because the common γ­chain is shared by many cytokine 
receptors (receptors for IL­2, IL­4, IL­7, IL­9, IL­15, and 
IL­21), mutations that result in a non­functional common 
γ­chain  cause  widespread  defects  in  IL  signaling  and 
failure of B and T cells to develop and mature. This is a 
rather profound example, and knowledge of the respon­
sible gene has opened avenues for therapeutic inter  ven­
tion in cases of X­linked SCID, where gene transfer of the 
normal CD132 appears to be a promising, even curative, 
treatment  modality  [4,5].  Similar  observations  and 
clinical conclusions have been made with another form 
of  SCID  caused  by  defects  in  the  variable,  diversity, 
joining recombination process [6].
Partial immune deficiency, referring to the inactivation 
of a single immune pathway due to genetic mutations in 
one  or  more  members  of  the  network,  was  initially 
suspected to act in a similar way to the SCID mutations, 
with patients having a predisposition to a wide variety of 
infections.  As  these  mutations  are  highly  penetrant, 
traditional  genetic  linkage  studies  have  been  able  to 
isolate the responsible genes and pathways for some of 
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clinical  presentations.  Notable  examples  include  the 
IFN­γ receptor (IFNGR1) in cases of severe mycobacterial 
infections [7], the lysosomal trafficking regulator (LYST) 
for Chediak­Higashi syndrome [8], and Bruton’s tyrosine 
kinase for X­linked agammaglobulinemia [9,10].
While the immune system has multiple pathways, each 
is thought to be active against a wide range of micro­
organisms.  Thus,  it  is  perhaps  surprising  that  the 
spectrum of infection susceptibility for these three genes 
appears to be fairly constrained. For example, IFNGR1 
mutations mainly predispose to mycobacterial infections, 
and LYST and Bruton’s tyrosine kinase mutations mainly 
predispose  to  predominantly  pyogenic  bacterial  infec­
tions  (for  example,  Streptococcus  pyogenes,  pneumo­
coccus,  and  Haemophilus  influenzae).  This  surprising 
finding  echoes  another  example:  that  of  complement 
deficiency  and  its  observed  confinement  to  increased 
susceptibility towards encapsulated bacteria, particularly 
Neisseria spp., despite consistent documentation on the 
importance  of  the  complement  pathway  in  common 
blood pathogen clearance [11,12].
Subtle changes to immune genes as a result of 
genetic polymorphism
In the last 5 years, advances in genomic research have 
enabled  the  use  of  the  GWAS  design,  permitting  the 
robust  identification  of  host  susceptibility  genes  for 
infectious  pathogens  in  increased  detail.  Although  the 
advent  of  GWAS  in  infectious  diseases  has  been  slow 
compared with GWAS in many other complex disease 
phenotypes [13,14], this approach has nonetheless allowed 
unprecedented identification (or confirmation) of genes 
associated with susceptibility to the infectious diseases 
studied so far [15­18].
Infectious  disease  genes  identified  via  the  GWAS 
approach have thus far been relatively ‘pathogen specific’, 
with cross­pathogen sharing being the exception rather 
than the rule.
The greatest surprise has related to observations within 
the human leukocyte antigen (HLA) locus, where broad­
based  sharing  between  pathogen  groups  could  be  ex­
pected, given the central role played by HLA in immune 
recognition of pathogens and the initiation of immune 
responses. However, recent GWAS have found that while 
different  HLA  alleles  appear  to  be  shared  between 
various auto­immune phenotypes (such as psoriasis [19], 
vitiligo [20], or systemic lupus erythematosus [21]), there 
appears to be little evidence of substantial susceptibility 
sharing  for  HLA  between  different  infectious  diseases. 
This disparity is striking even among supposedly ‘similar’ 
pathogen groups: a very strong contribution of the HLA 
locus  has  been  observed  for  leprosy  (Mycobacterium 
leprae) [15,22], but not for tuberculosis (Mycobacterium 
tuberculosis) susceptibility [23,24], highlighting the vast 
complexity of the immune response to diverse pathogens. 
This complexity is further shown in two genetic studies 
of vaccine response: while the HLA is crucial for success 
(or otherwise) for hepatitis B virus vaccination [25], it is 
not the case for H. influenzae type b vaccination [26].
Although  findings  thus  far  have  suggested  that  the 
main  pathways  underlying  susceptibility  to  pathogenic 
infection are pathogen specific, it is nonetheless relevant 
to understand similarities in the infection and invasion 
process for the very diverse pathogens that the human 
body encounters daily. For example, knowledge gleaned 
from the rare primary immune deficiencies has shown 
that  defects  in  extremely  central  components  of  the 
immune system result in broad, general susceptibility to 
multiple infectious diseases. Elucidation of the respon­
sible genes and pathways often yields considerable insight 
into  disease  mechanisms  and  pathogenesis,  and  can 
inform medical treatment (a good example being the case 
of  X­linked  agammaglobulinemia  where  common  anti­
biotic  treatments  do  not  suffice,  and  immunoglobulin 
replacement is necessary). If some of these therapeutic 
findings could be extended to the commoner forms of 
infection that clinicians encounter on a daily basis, this 
could have an immediate public health impact.
Genomic approaches have played a supporting role in 
the identification of potential therapeutic targets. One of 
the  virulent  capabilities  of  Neisseria  meningitidis  is  its 
ability to recruit human factor H (encoded by CFH) via 
molecular  mimicry  [27],  thus  avoiding  complement­
mediated killing of the bacterium. A recently completed 
GWAS on host susceptibility to meningococcal disease 
has shown that genetic polymorphisms within CFH as 
well as CFH­related genes are very strongly associated 
with susceptibility to meningococcal disease [18]. As the 
bacterial  factor  H­binding  protein  is  now  a  strong 
meningo  coccal  vaccine  candidate  [28],  it  is  clear  that 
genomic  approaches  can  be  used  independently  to 
discover or to confirm therapeutic targets identified by 
functional approaches.
Leprosy,  tuberculosis,  Crohn’s  disease,  and  ulcerative 
colitis have also been the subjects of recent investigations. 
Indeed, genomic approaches have underlined the impor­
tance of the nucleotide­binding oligomerization domain 
containing  (NOD)2  signaling  cascade  in  inflammatory 
and infectious diseases. Different members of the path­
way (NOD2, TNFSF15, and RIPK2) have been strongly 
implicated (P < 10­10) in susceptibility to leprosy [15,29], 
as  well  as  Crohn’s  disease,  which  is  an  inflammatory 
bowel disease with substantial links to infectious agents 
[30,31]. However, observations by us and others [24] do 
not  implicate  NOD2  pathway  members  as  strongly  in 
tuberculosis susceptibility. The same has been observed 
for CARD9 (a member of the extended NOD family of 
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ative colitis susceptibility [32] and functionally implicated 
in tuberculosis [33], but not with leprosy [15].
Another  gene  observed  to  be  a  strong  (P  <  10­10) 
suscep  tibility  factor  for  leprosy  is  TNFSF15  [15].  The 
exact same SNP (rs6478108) has also been found to be 
strongly associated (P < 10­10) with Crohn’s disease [34]. 
However, the minor allele has been found to be associated 
with increased risk of leprosy, but with decreased risk of 
Crohn’s disease. This suggests that differential regulation 
of the immune response appears to be critical to reach a 
balance between protection from invading pathogens and 
susceptibility to inflammatory disorders, thus highlight­
ing TNFSF15 as a potential therapeutic target in manipu­
lation of the strength of the immune response.
Indeed, the disparity in susceptibility genes for Crohn’s 
disease and ulcerative colitis (different members of the 
pathogen­sensing CARD family are involved: NOD2 for 
Crohn’s,  and  CARD9  for  ulcerative  colitis)  is  likely  to 
reflect  different  sites  of  pathology,  different  bacterial 
spectra, and therefore different mechanisms for microbial 
recognition. Strikingly, there is evidence suggesting that 
the downstream, cytokine­mediated pathogenesis path­
ways  (for  example,  those  involving  IL­23)  could  be 
common across both diseases [32].
Missing ‘shared susceptibility’?
The majority of evidence collected so far from genomic 
approaches  appears  to  suggest  that,  barring  specific 
exceptions,  common  host  susceptibility  to  different 
invad  ing pathogens appears to be controlled by discrete 
genes  and  pathways.  As  genomic  approaches  are  still 
limited  in  resolution,  there  is  a  possibility  that  truly 
shared mechanisms governing susceptibility across mul­
tiple pathogen groups have yet to be found. This seems to 
be  likely  in  view  of  the  finite  number  of  pathogen­
recognizing  receptors  available  at  the  first  lines  of 
defence,  coupled  with  their  convergent,  downstream 
signaling pathways. An example for ‘shared susceptibility’ 
would be TIRAP, which encodes a common adaptor for 
two major pathogen­sensing receptors (TLR2 and TLR4); 
an inactivating mutation (S180L) within TIRAP appears 
to associate with susceptibility to invasive pneumococcus 
and H. influenzae, as well as Trypanosoma cruzi infec­
tions [26,35,36], with a yet unconfirmed association with 
tuberculosis [37,38].
Considering the evidence now available, there is reason 
to believe that host susceptibility to infection could be 
specific and ‘mechanism dependent’ in terms of pathogen 
recognition  and  the  site  of  infection,  with  shared 
common  signaling  pathways  playing  an  important  role 
down  stream of pathogen contact points.
A  further  benefit  in  the  large­scale  deployment  of 
hypothesis­free  genomic  approaches  is  that  they  could 
help in establishing the etiology of certain autoimmune 
diseases  where  infectious  diseases  have  long  been 
suspected  ­  but  not  confirmed  ­  to  be  a  predisposing 
factor. For example, in the case of type 1 diabetes, GWAS 
have  implicated  an  extraordinary  number  of  immune­
related  genes,  some  of  which  overlap  with  infection 
pathways, thus lending credence to the above hypothesis.
Genomic  approaches  have  resulted  in  improved 
treatment strategies for patients with severe and partial 
immune deficiencies by identifying the deficient protein 
component(s),  but  for  many  of  the  common  infections, 
due to their complex nature, genomic approaches have not 
yet  been  as  fruitful  in  informing  medical  treatment. 
Emerging  antibiotic  resistance  is  putting  additional 
pressure  on  research  efforts  in  host  and  pathogen 
genomics for further improvement of therapeutic strategy 
beyond antimicrobial treatment, but there is hope that this 
research will lead to novel human protein­based therapies.
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